Jan 16 (Reuters) - Mylan has agreed to pay $73.5 million to settle a class action lawsuit by drug wholesalers accusing the drugmaker of scheming to overcharge them for EpiPen allergy treatment ...

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine ... The FDA approval was awarded to Mylan, which is now part of Viatris after merging with Pfizer's ...